Annual Net Income
-$21.49 M
+$4.79 M+18.22%
31 December 2023
Summary:
Lineage Cell Therapeutics annual net profit is currently -$21.49 million, with the most recent change of +$4.79 million (+18.22%) on 31 December 2023. During the last 3 years, it has fallen by -$837.00 thousand (-4.05%). LCTX annual net income is now -164.00% below its all-time high of $33.57 million, reached on 31 December 2016.LCTX Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
-$3.03 M
+$2.73 M+47.33%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly net profit is currently -$3.03 million, with the most recent change of +$2.73 million (+47.33%) on 30 September 2024. Over the past year, it has increased by +$4.08 million (+57.33%). LCTX quarterly net income is now -104.55% below its all-time high of $66.72 million, reached on 30 September 2018.LCTX Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
-$20.11 M
+$4.08 M+16.85%
30 September 2024
Summary:
Lineage Cell Therapeutics TTM net profit is currently -$20.11 million, with the most recent change of +$4.08 million (+16.85%) on 30 September 2024. Over the past year, it has increased by +$2.95 million (+12.81%). LCTX TTM net income is now -120.12% below its all-time high of $99.96 million, reached on 31 March 2017.LCTX TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +18.2% | +57.3% | +12.8% |
| 3 y3 years | -4.0% | +61.2% | -67.7% |
| 5 y5 years | +53.3% | +81.6% | +61.5% |
LCTX Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -4.0% | +50.0% | at high | +89.5% | -67.7% | +60.3% |
| 5 y | 5 years | -83.5% | +53.3% | -249.3% | +89.5% | -71.8% | +66.2% |
| alltime | all time | -164.0% | +54.3% | -104.5% | +95.8% | -120.1% | +84.9% |
Lineage Cell Therapeutics Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.03 M(-47.3%) | -$20.11 M(-16.9%) |
| June 2024 | - | -$5.76 M(-12.0%) | -$24.19 M(+2.2%) |
| Mar 2024 | - | -$6.54 M(+37.0%) | -$23.66 M(+10.1%) |
| Dec 2023 | -$21.49 M(-18.2%) | -$4.78 M(-32.8%) | -$21.49 M(-6.8%) |
| Sept 2023 | - | -$7.11 M(+36.0%) | -$23.07 M(+4.7%) |
| June 2023 | - | -$5.23 M(+19.6%) | -$22.02 M(-6.5%) |
| Mar 2023 | - | -$4.37 M(-31.2%) | -$23.56 M(-10.3%) |
| Dec 2022 | -$26.27 M(-38.9%) | -$6.35 M(+4.7%) | -$26.27 M(-46.3%) |
| Sept 2022 | - | -$6.07 M(-10.3%) | -$48.91 M(-3.5%) |
| June 2022 | - | -$6.76 M(-4.6%) | -$50.66 M(+4.1%) |
| Mar 2022 | - | -$7.09 M(-75.6%) | -$48.69 M(+13.2%) |
| Dec 2021 | -$43.02 M(+108.3%) | -$28.99 M(+270.6%) | -$43.02 M(+258.6%) |
| Sept 2021 | - | -$7.82 M(+63.4%) | -$11.99 M(+0.5%) |
| June 2021 | - | -$4.79 M(+238.1%) | -$11.93 M(-12.7%) |
| Mar 2021 | - | -$1.42 M(-169.7%) | -$13.67 M(-33.8%) |
| Dec 2020 | -$20.65 M(+76.4%) | $2.03 M(-126.2%) | -$20.65 M(-24.0%) |
| Sept 2020 | - | -$7.76 M(+19.0%) | -$27.16 M(-24.4%) |
| June 2020 | - | -$6.52 M(-22.3%) | -$35.91 M(-39.6%) |
| Mar 2020 | - | -$8.40 M(+87.4%) | -$59.42 M(+407.5%) |
| Dec 2019 | -$11.71 M(-74.5%) | -$4.48 M(-72.8%) | -$11.71 M(-77.6%) |
| Sept 2019 | - | -$16.50 M(-45.0%) | -$52.18 M(-268.0%) |
| June 2019 | - | -$30.03 M(-176.4%) | $31.05 M(-45.4%) |
| Mar 2019 | - | $39.31 M(-187.4%) | $56.87 M(-223.7%) |
| Dec 2018 | -$45.99 M(+130.2%) | -$44.95 M(-167.4%) | -$45.99 M(-37.0%) |
| Sept 2018 | - | $66.72 M(-1683.0%) | -$72.97 M(-41.8%) |
| June 2018 | - | -$4.21 M(-93.4%) | -$125.38 M(-5.6%) |
| Mar 2018 | - | -$63.55 M(-11.7%) | -$132.81 M(+564.9%) |
| Dec 2017 | -$19.98 M(-159.5%) | -$71.93 M(-602.3%) | -$19.98 M(-142.6%) |
| Sept 2017 | - | $14.32 M(-222.9%) | $46.88 M(-26.5%) |
| June 2017 | - | -$11.65 M(-123.6%) | $63.76 M(-36.2%) |
| Mar 2017 | - | $49.29 M(-1071.2%) | $99.96 M(+197.8%) |
| Dec 2016 | $33.57 M(-171.4%) | -$5.08 M(-116.3%) | $33.56 M(+33.1%) |
| Sept 2016 | - | $31.20 M(+27.1%) | $25.21 M(-228.5%) |
| June 2016 | - | $24.55 M(-243.5%) | -$19.61 M(-63.6%) |
| Mar 2016 | - | -$17.11 M(+27.5%) | -$53.85 M(+14.8%) |
| Dec 2015 | -$46.99 M(+29.1%) | -$13.42 M(-1.5%) | -$46.91 M(+6.4%) |
| Sept 2015 | - | -$13.63 M(+40.6%) | -$44.07 M(+13.8%) |
| June 2015 | - | -$9.69 M(-4.7%) | -$38.71 M(+0.4%) |
| Mar 2015 | - | -$10.17 M(-3.9%) | -$38.54 M(+5.7%) |
| Dec 2014 | -$36.41 M(-17.0%) | -$10.58 M(+28.0%) | -$36.47 M(-19.8%) |
| Sept 2014 | - | -$8.27 M(-13.2%) | -$45.50 M(-1.6%) |
| June 2014 | - | -$9.52 M(+17.5%) | -$46.23 M(+4.5%) |
| Mar 2014 | - | -$8.10 M(-58.7%) | -$44.26 M(+0.9%) |
| Dec 2013 | -$43.88 M(+104.8%) | -$19.61 M(+117.8%) | -$43.88 M(+44.8%) |
| Sept 2013 | - | -$9.00 M(+19.3%) | -$30.31 M(+15.4%) |
| June 2013 | - | -$7.55 M(-2.2%) | -$26.26 M(+8.7%) |
| Mar 2013 | - | -$7.72 M(+27.9%) | -$24.17 M(+12.8%) |
| Dec 2012 | -$21.43 M(+29.7%) | -$6.04 M(+21.7%) | -$21.42 M(+3.2%) |
| Sept 2012 | - | -$4.96 M(-9.1%) | -$20.75 M(+6.2%) |
| June 2012 | - | -$5.46 M(+9.7%) | -$19.53 M(+6.4%) |
| Mar 2012 | - | -$4.97 M(-7.2%) | -$18.35 M(+9.6%) |
| Dec 2011 | -$16.52 M(+47.7%) | -$5.36 M(+43.4%) | -$16.74 M(+16.7%) |
| Sept 2011 | - | -$3.74 M(-12.6%) | -$14.35 M(-6.1%) |
| June 2011 | - | -$4.28 M(+27.2%) | -$15.28 M(+15.2%) |
| Mar 2011 | - | -$3.36 M(+13.2%) | -$13.26 M(+18.6%) |
| Dec 2010 | -$11.18 M(+117.4%) | -$2.97 M(-36.4%) | -$11.19 M(+64.6%) |
| Sept 2010 | - | -$4.67 M(+106.7%) | -$6.80 M(+19.2%) |
| June 2010 | - | -$2.26 M(+75.6%) | -$5.70 M(+16.0%) |
| Mar 2010 | - | -$1.29 M(-190.6%) | -$4.91 M(-4.5%) |
| Dec 2009 | -$5.14 M(+36.1%) | $1.42 M(-139.7%) | -$5.14 M(-36.7%) |
| Sept 2009 | - | -$3.57 M(+143.0%) | -$8.13 M(+44.3%) |
| June 2009 | - | -$1.47 M(-3.1%) | -$5.63 M(+16.8%) |
| Mar 2009 | - | -$1.52 M(-3.0%) | -$4.82 M(+27.6%) |
| Dec 2008 | -$3.78 M | -$1.56 M(+45.3%) | -$3.78 M(+48.7%) |
| Sept 2008 | - | -$1.08 M(+62.5%) | -$2.54 M(+51.4%) |
| June 2008 | - | -$662.80 K(+39.2%) | -$1.68 M(+23.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | -$476.00 K(+45.7%) | -$1.36 M(-5.4%) |
| Dec 2007 | -$1.44 M(-22.9%) | -$326.80 K(+53.1%) | -$1.44 M(-3.5%) |
| Sept 2007 | - | -$213.50 K(-38.0%) | -$1.49 M(-7.8%) |
| June 2007 | - | -$344.10 K(-37.9%) | -$1.62 M(-16.7%) |
| Mar 2007 | - | -$553.90 K(+46.3%) | -$1.94 M(+4.1%) |
| Dec 2006 | -$1.86 M(-10.1%) | -$378.60 K(+11.4%) | -$1.86 M(-5.6%) |
| Sept 2006 | - | -$340.00 K(-49.1%) | -$1.98 M(-3.7%) |
| June 2006 | - | -$667.80 K(+39.6%) | -$2.05 M(+12.3%) |
| Mar 2006 | - | -$478.20 K(-2.4%) | -$1.83 M(-12.0%) |
| Dec 2005 | -$2.07 M(-32.8%) | -$489.90 K(+18.0%) | -$2.07 M(-2.7%) |
| Sept 2005 | - | -$415.10 K(-6.2%) | -$2.13 M(-1.7%) |
| June 2005 | - | -$442.70 K(-39.1%) | -$2.17 M(+0.0%) |
| Mar 2005 | - | -$726.60 K(+32.6%) | -$2.17 M(-29.7%) |
| Dec 2004 | -$3.09 M(+77.1%) | -$548.10 K(+21.2%) | -$3.09 M(-1.6%) |
| Sept 2004 | - | -$452.10 K(+2.2%) | -$3.14 M(+35.1%) |
| June 2004 | - | -$442.30 K(-73.1%) | -$2.32 M(-11.9%) |
| Mar 2004 | - | -$1.64 M(+174.7%) | -$2.63 M(+51.2%) |
| Dec 2003 | -$1.74 M(-38.8%) | -$598.10 K(-265.2%) | -$1.74 M(-9.3%) |
| Sept 2003 | - | $362.00 K(-148.0%) | -$1.92 M(-32.9%) |
| June 2003 | - | -$754.90 K(+0.5%) | -$2.86 M(-1.0%) |
| Mar 2003 | - | -$751.10 K(-3.3%) | -$2.89 M(+1.6%) |
| Dec 2002 | -$2.84 M(-22.2%) | -$776.50 K(+34.1%) | -$2.85 M(+5.7%) |
| Sept 2002 | - | -$578.90 K(-26.1%) | -$2.69 M(-10.8%) |
| June 2002 | - | -$783.20 K(+10.9%) | -$3.02 M(-10.0%) |
| Mar 2002 | - | -$706.40 K(+13.6%) | -$3.35 M(-6.8%) |
| Dec 2001 | -$3.66 M(-25.7%) | -$622.00 K(-31.1%) | -$3.60 M(-10.6%) |
| Sept 2001 | - | -$903.40 K(-19.3%) | -$4.03 M(-7.4%) |
| June 2001 | - | -$1.12 M(+17.7%) | -$4.35 M(-4.6%) |
| Mar 2001 | - | -$951.70 K(-9.4%) | -$4.56 M(-7.5%) |
| Dec 2000 | -$4.92 M(-10.1%) | -$1.05 M(-14.3%) | -$4.93 M(-8.0%) |
| Sept 2000 | - | -$1.23 M(-7.9%) | -$5.35 M(-16.7%) |
| June 2000 | - | -$1.33 M(+0.8%) | -$6.43 M(+5.4%) |
| Mar 2000 | - | -$1.32 M(-10.8%) | -$6.10 M(+9.3%) |
| Dec 1999 | -$5.48 M(+160.9%) | -$1.48 M(-35.7%) | -$5.58 M(+36.1%) |
| Sept 1999 | - | -$2.30 M(+130.0%) | -$4.10 M(+41.4%) |
| June 1999 | - | -$1.00 M(+25.0%) | -$2.90 M(+20.8%) |
| Mar 1999 | - | -$800.00 K(-27.3%) | -$2.40 M(-27.3%) |
| Dec 1998 | -$2.10 M(-40.0%) | - | - |
| Sept 1998 | - | -$1.10 M(+120.0%) | -$3.30 M(+3.1%) |
| June 1998 | - | -$500.00 K(-54.5%) | -$3.20 M(-13.5%) |
| June 1998 | -$3.50 M(+16.7%) | - | - |
| Mar 1998 | - | -$1.10 M(+83.3%) | -$3.70 M(+19.4%) |
| Dec 1997 | - | -$600.00 K(-40.0%) | -$3.10 M(-6.1%) |
| Sept 1997 | - | -$1.00 M(0.0%) | -$3.30 M(+10.0%) |
| June 1997 | -$3.00 M(+50.0%) | -$1.00 M(+100.0%) | -$3.00 M(+20.0%) |
| Mar 1997 | - | -$500.00 K(-37.5%) | -$2.50 M(-3.8%) |
| Dec 1996 | - | -$800.00 K(+14.3%) | -$2.60 M(+8.3%) |
| Sept 1996 | - | -$700.00 K(+40.0%) | -$2.40 M(+20.0%) |
| June 1996 | -$2.00 M(-16.7%) | -$500.00 K(-16.7%) | -$2.00 M(-9.1%) |
| Mar 1996 | - | -$600.00 K(0.0%) | -$2.20 M(0.0%) |
| Dec 1995 | - | -$600.00 K(+100.0%) | -$2.20 M(0.0%) |
| Sept 1995 | - | -$300.00 K(-57.1%) | -$2.20 M(-8.3%) |
| June 1995 | -$2.40 M(+60.0%) | -$700.00 K(+16.7%) | -$2.40 M(+14.3%) |
| Mar 1995 | - | -$600.00 K(0.0%) | -$2.10 M(+16.7%) |
| Dec 1994 | - | -$600.00 K(+20.0%) | -$1.80 M(+12.5%) |
| Sept 1994 | - | -$500.00 K(+25.0%) | -$1.60 M(+14.3%) |
| June 1994 | -$1.50 M(+25.0%) | -$400.00 K(+33.3%) | -$1.40 M(+7.7%) |
| Mar 1994 | - | -$300.00 K(-25.0%) | -$1.30 M(+8.3%) |
| Dec 1993 | - | -$400.00 K(+33.3%) | -$1.20 M(+9.1%) |
| Sept 1993 | - | -$300.00 K(0.0%) | -$1.10 M(0.0%) |
| June 1993 | -$1.20 M(+71.4%) | -$300.00 K(+50.0%) | -$1.10 M(+10.0%) |
| Mar 1993 | - | -$200.00 K(-33.3%) | -$1.00 M(0.0%) |
| Dec 1992 | - | -$300.00 K(0.0%) | -$1.00 M(+42.9%) |
| Sept 1992 | - | -$300.00 K(+50.0%) | -$700.00 K(+75.0%) |
| June 1992 | -$700.00 K | -$200.00 K(0.0%) | -$400.00 K(+100.0%) |
| Mar 1992 | - | -$200.00 K | -$200.00 K |
FAQ
- What is Lineage Cell Therapeutics annual net profit?
- What is the all time high annual net income for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual net income year-on-year change?
- What is Lineage Cell Therapeutics quarterly net profit?
- What is the all time high quarterly net income for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly net income year-on-year change?
- What is Lineage Cell Therapeutics TTM net profit?
- What is the all time high TTM net income for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics TTM net income year-on-year change?
What is Lineage Cell Therapeutics annual net profit?
The current annual net income of LCTX is -$21.49 M
What is the all time high annual net income for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual net profit is $33.57 M
What is Lineage Cell Therapeutics annual net income year-on-year change?
Over the past year, LCTX annual net profit has changed by +$4.79 M (+18.22%)
What is Lineage Cell Therapeutics quarterly net profit?
The current quarterly net income of LCTX is -$3.03 M
What is the all time high quarterly net income for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly net profit is $66.72 M
What is Lineage Cell Therapeutics quarterly net income year-on-year change?
Over the past year, LCTX quarterly net profit has changed by +$4.08 M (+57.33%)
What is Lineage Cell Therapeutics TTM net profit?
The current TTM net income of LCTX is -$20.11 M
What is the all time high TTM net income for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high TTM net profit is $99.96 M
What is Lineage Cell Therapeutics TTM net income year-on-year change?
Over the past year, LCTX TTM net profit has changed by +$2.95 M (+12.81%)